Tools
Tools
Collinson, F, Qian, W, Fossati, R, Lissoni, A, Williams, C, Parmar, M, Ledermann, J, Colombo, N and Swart, A 
ORCID: https://orcid.org/0000-0002-9359-6995
and
on behalf of the ICON1 collaborators
(2014)
Optimal treatment of early-stage ovarian cancer.
Annals of Oncology, 25 (6).
pp. 1165-1171.
ISSN 0923-7534
Abstract
There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated benefit in both overall survival (OS) and recurrence-free survival (RFS) with adjuvant chemotherapy. We report results of 10-year follow-up to establish whether benefits are maintained longer-term and discuss how this and other available evidence from randomised trials can be used to guide treatment options regarding the need for, and choice of, adjuvant chemotherapy regimen.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | early-stage ovarian cancer,adjuvant chemotherapy,icon1,icon3,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Cardiovascular and Metabolic Health Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) |
| Depositing User: | Pure Connector |
| Date Deposited: | 30 May 2014 20:08 |
| Last Modified: | 03 Nov 2022 15:36 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/48507 |
| DOI: | 10.1093/annonc/mdu116 |
Actions (login required)
 |
View Item |